Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SAN DIEGO, May 31, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.
The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
